EntreMed sells royalty interest in Thalomid for $22.4mm
Executive Summary
Royalty Pharma AG has agreed to give EntreMed (antiangiogenesis drugs) $22.4mm in exchange for a percentage of royalties from its cancer drug Thalomid (thalidomide).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice